Otenabant

Otenabant

Clinical data
ATC code	none
Identifiers
IUPAC name 1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-4-(ethylamino)piperidine-4- carboxamide
CAS Number	686344-29-6 Y
PubChem CID	10052040
ChemSpider	8227602 N
UNII	J8211Y53EF
KEGG	D09362 Y
ChEMBL	ChEMBL562668 N
CompTox Dashboard (EPA)	DTXSID20988316
Chemical and physical data
Formula	C25H25Cl2N7O
Molar mass	510.42 g·mol−1
3D model (JSmol)	Interactive image
SMILES CCNC1(CCN(CC1)C2=NC=NC3=C2N=C(N3C4=CC=C(C=C4)Cl)C5=CC=CC=C5Cl)C(=O)N
InChI InChI=1S/C25H25Cl2N7O/c1-2-31-25(24(28)35)11-13-33(14-12-25)22-20-23(30-15-29-22)34(17-9-7-16(26)8-10-17)21(32-20)18-5-3-4-6-19(18)27/h3-10,15,31H,2,11-14H2,1H3,(H2,28,35) N Key:UNAZAADNBYXMIV-UHFFFAOYSA-N N
NY (what is this?)  (verify)

Otenabant (CP-945,598) is a drug which acts as a potent and highly selective CB₁ antagonist. It was developed by Pfizer for the treatment of obesity, but development for this application has been discontinued following the problems seen during clinical use of the similar drug rimonabant.

See also

• Cannabinoid receptor antagonist